The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer
Ritu Yadav,Rinku Khatkar,Kenneth C-H Yap,Chloe Yun-Hui Kang,Juncheng Lyu,Rahul Kumar Singh,Surojit Mandal,Adrija Mohanta,Hiu Yan Lam,Elena Okina,Rajiv Ranjan Kumar,Vivek Uttam,Uttam Sharma,Manju Jain,Hridayesh Prakash,Hardeep Singh Tuli,Alan Prem Kumar,Aklank Jain
DOI: https://doi.org/10.1038/s41420-024-02182-1
2024-09-30
Cell Death Discovery
Abstract:Lung cancer is a severe challenge to the health care system with intrinsic resistance to first and second-line chemo/radiotherapies. In view of the sterile environment of lung cancer, several immunotherapeutic drugs including nivolumab, pembrolizumab, atezolizumab, and durvalumab are currently being used in clinics globally with the intention of releasing exhausted T-cells back against refractory tumor cells. Immunotherapies have a limited response rate and may cause immune-related adverse events (irAEs) in some patients. Hence, a deeper understanding of regulating immune checkpoint interactions could significantly enhance lung cancer treatments. In this review, we explore the role of miRNAs in modulating immunogenic responses against tumors. We discuss various aspects of how manipulating these checkpoints can bias the immune system's response against lung cancer. Specifically, we examine how altering the miRNA profile can impact the activity of various immune checkpoint inhibitors, focusing on the PD-1/PD-L1 pathway within the complex landscape of lung cancer. We believe that a clear understanding of the host's miRNA profile can influence the efficacy of checkpoint inhibitors and significantly contribute to existing immunotherapies for lung cancer patients. Additionally, we discuss ongoing clinical trials involving immunotherapeutic drugs, both as standalone treatments and in combination with other therapies, intending to advance the development of immunotherapy for lung cancer.
cell biology